drugset
drugset / Trial / NCT01809353

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

NCT01809353 ↗

Phase 1 Completed 32 enrolled Janssen Research & Development, LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and safety of JNJ-54452840 in healthy participants.

Timeline

Start
2013-07
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MIBENRATIDE Protein / enzyme biologic 20 mg Intravenous
Subject MIBENRATIDE Protein / enzyme biologic 80 mg Intravenous
Subject MIBENRATIDE Protein / enzyme biologic 240 mg Intravenous

Indications

No indication recorded.